Akademik Veri Yönetim Sistemi
THORACIC AND CARDIOVASCULAR SURGEON, cilt.66, sa.4, ss.328-332, 2018 (SCI-Expanded)
Byackground To evaluate the results of patients with chronic hepatitis C virus (HCV) following cardiac surgery in the TurcoSCORE (TrS) database. Methods Sixty patients with HCV who underwent cardiac surgery between 2005 and 2016 in our clinic out of a total 8,018 patients from the TrS database were included in the study. The perioperative morbidity and mortality rates in these patients were compared with a matched cohort. Results The mean follow-up time was 96.6 12.3 months. Hospital mortality rates (HCV group 5% vs. control group 1.7%, p 1/4 0.61) were similar between the groups. No significant difference was found in the duration of cardiopulmonary bypass (HCV 79.1 12.3 vs. control 82.6 11.8, p 1/4 0.88) and cross clamps (HCV 33.4 6.9 vs control 33.8 7.2 p 1/4 0.76) between the two groups. The rate of patients who were revised due to postoperative hemorrhage was significantly higher in the HCV arm compared with the matched cohort (HCV 13.3% vs. control 1.7%, p < 0.05). Although the measured prothrombin time (PT) and international normalized ratio (INR) in the postoperative 24th hour were in normal ranges in both arms, they were significantly higher in the HCV arm (HCV 11.2 1.2 vs. control 10.5 0.8, p < 0.05; HCV 0.99 0.06, vs. control 0.92 0.03, p < 0.0001). Conclusion The presence of HCV can be an important prognostic factor formorbidity in patients undergoing cardiac surgery. It can also play an important role in the risk models generated for cardiac surgery.